Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743432 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL3945901 | 1.00 | ADORA1 (0.68) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL743029 | 0.91 | NT5E (0.73) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL743030 | 0.91 | NT5E (0.73) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL741504 | 0.90 | PAX8 (0.75) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL741505 | 0.90 | PAX8 (0.75) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL4797211 | 0.89 | SLC29A1 (0.70) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL3949659 | 0.88 | ADORA2A (0.63) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL5393426 | 0.88 | ADORA2A (0.63) | ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL7080749 | 0.87 | ADORA3 (0.80) | ADORA1ADORA3ADORA2AADORA2BNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430036-B1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2014-03-06 | — | — | US | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
| EP-2430036-A1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130233-A1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-11-18 | — | — | WO | disclosed |
| US-7262176-B2 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1414837-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040116376-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1414837-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20030078232-A1 | Adenosine receptor A3 agonists | CV THERAPEUTICS, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2003014137-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | PNP, NUDT1, TYMP | ADORA1 340/4885ADORA3 363/4885ADORA2A 111/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | ADORA1 147/4885ADORA3 191/4885ADORA2A 76/4885 |
| US-20030078232-A1 | Adenosine receptor A3 agonists | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885ADORA3 1/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.